Real-World check: does adding nivolumab to chemo help stomach cancer patients?
NCT ID NCT05334719
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well a combination of nivolumab (an immunotherapy drug) and chemotherapy works for people with advanced or recurrent stomach cancer who haven't had treatment before. It involved 500 patients in Japan and tracked things like how long the cancer stayed under control and any side effects. The goal was to see how this treatment performs in everyday medical practice, not just in controlled experiments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Minato-ku, Tokyo, 1050001, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
- Could a simple painkiller combo replace opioids after stomach cancer surgery?
- Default option nudge may boost cancer screening in High-Risk groups
- Acupuncture with a jolt: could needles shield nerves from chemo?